Literature DB >> 15115918

A 6 bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels.

Michael V Mandola1, Jan Stoehlmacher, Wu Zhang, Susan Groshen, Mimi C Yu, Syma Iqbal, Heinz-Josef Lenz, Robert D Ladner.   

Abstract

OBJECTIVE: A 6 bp deletion polymorphism in the thymidylate synthase (TS) gene was investigated in order to determine its function.
METHODS: A luciferase system was used to investigate the function of the 6 bp/1494 polymorphism in vitro. A group of 43 patients with colorectal carcinoma were evaluated for the 6 bp/1494 polymorphism and for intratumoral TS mRNA levels in vivo.
RESULTS: The 3'UTR of TS containing the +6 bp polymorphism resulted in an approximate 35% decrease in luciferase activity and mRNA levels, while the TS-3'UTR bearing the -6 bp deletion resulted in an approximate 70% decrease in luciferase activity and mRNA levels. The TS-3'UTR construct containing the -6 bp/1494 deletion also had a higher rate of message degradation compared to the +6 bp/1494 construct. Individuals homozygous for the insertion (+6 bp/+6 bp) had significantly higher TS mRNA levels compared to individuals that were homozygous for the deletion (-6 bp/-6 bp) (P < 0.007). We determined the frequency of the -6 bp/1494 deletion polymorphism to be 41% in non-Hispanic whites, 26% in Hispanic whites, 52% in African-Americans and 76% in Singapore Chinese.
CONCLUSIONS: These results suggest that the -6 bp/1494 deletion polymorphism in the 3'UTR of TS is associated with decreased mRNA stability in vitro and lower intratumoral TS expression in vivo. Further, the 6 bp/1494 polymorphism varies greatly within different ethnic populations and is in linkage disequilibrium with the TS 5' tandem repeat enhancer polymorphism. Taken together, these data suggest that the 6 bp/1494 polymorphism may be a useful screening tool in predicting TS mRNA expression. Copyright 2004 Lippincott Williams & Wilkins

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15115918     DOI: 10.1097/00008571-200405000-00007

Source DB:  PubMed          Journal:  Pharmacogenetics        ISSN: 0960-314X


  82 in total

Review 1.  Part 1: background, methodology, and clinical adoption of pharmacogenetics.

Authors:  Maarten J Deenen; Annemieke Cats; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

Review 2.  Three decades of low-dose methotrexate in rheumatoid arthritis: can we predict toxicity?

Authors:  Vasco C Romão; Aurea Lima; Miguel Bernardes; Helena Canhão; João Eurico Fonseca
Journal:  Immunol Res       Date:  2014-12       Impact factor: 2.829

3.  Pharmacogenetics: implementing personalized medicine.

Authors:  Enrico Mini; Stefania Nobili
Journal:  Clin Cases Miner Bone Metab       Date:  2009-01

4.  Beyond Thymidylate Synthase and Dihydrofolate Reductase: Impact of Non-coding microRNAs in Anticancer Chemoresistance.

Authors:  Jingfang Ju
Journal:  Curr Enzym Inhib       Date:  2012-09-01

Review 5.  Genetic markers of treatment response in rheumatoid arthritis.

Authors:  Joanna Wesoly; Judith A M Wessels; Henk-Jan Guchelaar; Tom W J Huizinga
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

Review 6.  A systematic analysis of disease-associated variants in the 3' regulatory regions of human protein-coding genes II: the importance of mRNA secondary structure in assessing the functionality of 3' UTR variants.

Authors:  Jian-Min Chen; Claude Férec; David N Cooper
Journal:  Hum Genet       Date:  2006-06-29       Impact factor: 4.132

Review 7.  The role of pharmacogenetics in cancer therapeutics.

Authors:  Wei Peng Yong; Federico Innocenti; Mark J Ratain
Journal:  Br J Clin Pharmacol       Date:  2006-07       Impact factor: 4.335

8.  Thymidylate synthase polymorphisms are associated to therapeutic outcome of advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.

Authors:  Aurea Lima; Vítor Seabra; Sandra Martins; Ana Coelho; António Araújo; Rui Medeiros
Journal:  Mol Biol Rep       Date:  2014-02-20       Impact factor: 2.316

9.  Integrin genetic variants and stage-specific tumor recurrence in patients with stage II and III colon cancer.

Authors:  P Bohanes; D Yang; F Loupakis; M J LaBonte; A Gerger; Y Ning; C Lenz; F Lenz; T Wakatsuki; W Zhang; L Benhaim; A El-Khoueiry; R El-Khoueiry; H-J Lenz
Journal:  Pharmacogenomics J       Date:  2014-12-09       Impact factor: 3.550

10.  Green tea intake, MTHFR/TYMS genotype and breast cancer risk: the Singapore Chinese Health Study.

Authors:  Maki Inoue; Kim Robien; Renwei Wang; David J Van Den Berg; Woon-Puay Koh; Mimi C Yu
Journal:  Carcinogenesis       Date:  2008-07-31       Impact factor: 4.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.